Clarkston Capital Partners LLC Has $24.77 Million Stake in Ralliant Corporation $RAL

Clarkston Capital Partners LLC raised its holdings in Ralliant Corporation (NYSE:RAL) by 200.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 566,405 shares of the company’s stock after purchasing an additional 377,652 shares during the quarter. Clarkston Capital Partners LLC’s holdings in Ralliant were worth $24,769,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Envestnet Asset Management Inc. bought a new stake in shares of Ralliant during the second quarter worth $4,922,000. Bank of New York Mellon Corp acquired a new stake in shares of Ralliant in the second quarter valued at $32,655,000. Resona Asset Management Co. Ltd. bought a new position in shares of Ralliant in the second quarter valued at about $1,582,000. SouthState Corp bought a new position in shares of Ralliant in the second quarter valued at about $35,000. Finally, Savant Capital LLC acquired a new position in Ralliant during the 2nd quarter worth about $410,000.

Insider Activity at Ralliant

In other Ralliant news, Director Anelise Angelino Sacks acquired 2,000 shares of Ralliant stock in a transaction on Monday, February 9th. The shares were purchased at an average cost of $41.25 per share, with a total value of $82,500.00. Following the completion of the purchase, the director owned 5,403 shares in the company, valued at $222,873.75. The trade was a 58.77% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Karen M. Bick sold 5,485 shares of Ralliant stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the sale, the senior vice president directly owned 46,756 shares of the company’s stock, valued at $2,104,020. This represents a 10.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have acquired 8,145 shares of company stock worth $332,233 over the last 90 days.

Ralliant Trading Down 3.5%

Shares of RAL opened at $44.74 on Monday. The stock’s fifty day simple moving average is $48.94 and its 200-day simple moving average is $46.70. The firm has a market capitalization of $5.00 billion and a PE ratio of 22.83. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $57.02. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Ralliant’s payout ratio is currently 10.20%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Oppenheimer decreased their price objective on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, February 6th. Citigroup reduced their target price on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Truist Financial decreased their price target on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Barclays decreased their price target on shares of Ralliant from $60.00 to $52.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $45.00 price target on shares of Ralliant in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $50.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.